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The generation of compartmentalized
nanoparticles containing siRNA and cisplatin using
a multi-needle electrohydrodynamic strategy†
Maria F. Pina,a Wai Lau,b Kathrin Scherer,c Maryam Parhizkar,b Mohan Edirisingheb
and Duncan Craig *a
This study outlines a novel manufacturing technique for the generation of compartmentalized trilayered
nanoparticles loaded with an anti-cancer agent and siRNA as a platform for the combination treatment of
cancers. More speciﬁcally, we describe the use of a multi-needle electrohydrodynamic approach to
produce nanoparticles with high size speciﬁcity and scalable output, while allowing suitable environments
for each therapeutic agent. The inner polylactic-glycolic-acid (PLGA) layer was loaded with cisplatin while
the middle chitosan layer was loaded with siRNA. The corresponding polymeric solutions were character-
ized for their viscosity, surface tension and conductivity, while particle size was determined using
dynamic light scattering. The internal structure was studied using transmission electron microscopy (TEM)
and Structured Illumination Microscopy (SIM). The inclusion of cisplatin was studied using electron disper-
sive spectroscopy (EDS). We were able to generate nanoparticles of approximate size 130 nm with three
distinct layers containing an outer protective PLGA layer, a middle layer of siRNA and an inner layer of cis-
platin. These particles have the potential not only for uptake into tumors via the enhanced permeability
and retention (EPR) eﬀect but also the sequential release of the siRNA and chemotherapeutic agent,
thereby providing a means of overcoming challenges of targeting and tumor drug resistance.
Introduction
The potential of using combination regimes of diﬀerent
chemotherapeutic agents for the treatment of cancers1 is now
a widely used approach for increasing the eﬃcacy of treatment
for multi-resistant tumors. More recently, strategies involving
the combination of anticancer drugs and small interference
RNA (siRNA) have emerged; the use of siRNA allows the
silencing of specific drug-resistance genes, thereby reducing
tumor resistance to the chemotherapeutic agent.2–6 Although
the separate administration of the two actives has proved to be
advantageous, studies have recently indicated that if the
agents can be delivered simultaneously using a single carrier
system (co-delivery) this may enhance the therapeutic
eﬃciency of these formulations.7–9 For example, Sun and co-
authors were able to demonstrate that the co-delivery of Plk1
siRNA and paclitaxel had a greater inhibitory eﬀect on cell
proliferation than the two actives administered separately.10 In
this case, the authors used amphiphilic polymers that self-
assembled into micellar nanoparticles creating a hydrophobic
core and a cationic shell that allowed the simultaneous
loading of paclitaxel and siRNA, respectively. Similarly, Saad
et al. developed a multifunctional cationic liposomal delivery
system containing doxorubicin in the aqueous core and two
types of siRNA (for silencing of pump and non-pump drug
resistance) electrostatically bound to the surface.11 A further
general approach to deliver drug-siRNA combinations involves
the use of polymeric carriers such as poly(lactic-co-glycolic)
acid (PLGA), polycaprolactone (PCL), chitosan, polyethylene
glycol (PEG), polyethylenimine (PEI) and poly(2-aminoethyl
ethylene phosphate) (PPEEA). In general, polymeric nano-
particles are prepared via double emulsion solvent evaporation
techniques and have either a hydrophobic (PLGA or PCL) or a
hydrophilic (PEG) matrix that allows the encapsulation of
small molecules and cationic polymers (PEI, PPEEA or chito-
san) that enhance the loading eﬃciency of the anionic
siRNA.2,12 Inorganic delivery vectors such as mesoporous silica
nanoparticles4,5 and gold nanorods13 have also been use to
delivery such combination therapies.
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Despite the interest in developing co-administered systems,
combination systems present a number of unresolved
challenges. True compartmentalization in distinct, stable
environments is diﬃcult to achieve, particularly when there
are significant diﬀerences in the physicochemical properties
of the two actives such as molecular weight, hydrophobicity
and metabolic stability. This is especially important for siRNA
systems due to the environmental requirements associated
with maintaining stability. More specifically, siRNA is sensitive
to nuclease degradation and its hydrophilic and anionic
nature makes it unable to cross cellular membranes.
Therefore, siRNA-mediated silencing strongly depends on the
design of powerful delivery systems to (i) protect siRNA mole-
cules from enzymatic degradation, (ii) be internalized by the
cells and (iii) release of siRNA in the cell cytoplasm where the
RNAi machinery is located. A widely used approach for siRNA
delivery is the complexation with cationic polymers namely
chitosan which has the advantage of being biodegradable and
biocompatible, characteristics that are highly desired in a drug
delivery system.14,15 In addition, incompatibility between
siRNA and anticancer drugs can result in both chemical and
physical instability.16 Finally, one needs to consider whether
sequential release is required. In the case of siRNA-chemother-
apeutic systems, after the cellular uptake of the nanocarrier,
the siRNA cargo should ideally be released prior to the drug,
allowing enough time for the siRNA sensitizing eﬀect to take
place before the drug is released.17,18 For example, Yadav et al.
observed maximum therapeutic eﬀect when paclitaxel was
administered 24 h after the cells being treated with
P-glycoprotein (Pgp) siRNA as this permitted an eﬃcient
Pgp knock-down.19 Similar results were shown by Beh and
co-workers where maximum cytotoxicity of paclitaxel was
observed 48 h after Bcl-2 siRNA treatment.20 To date, there is
no carrier system available that is able to fulfil the require-
ments of complete individualization of the actives, environ-
ments conducive to siRNA stability and rational sequential
release.
The size range of the nanoparticles used in cancer therapy
should also be considered. Most of the tumors are known to
have an underdeveloped and thus show leaky vasculature,
leading to the process known as enhanced permeability and
retention (EPR), whereby macromolecules or nanoparticles can
escape the circulation into the tumor and accumulate in the
tumor site due to ineﬃcient drainage by the lymphatic
system.21 The EPR eﬀect can be observed in most human
cancers with the exception of hypovascular tumors such as
prostate or pancreatic cancers. Particles having a size between
100–200 nm have the highest potential for prolonged circula-
tion since they are small enough to avoid uptake by the liver
but suﬃciently large to avoid renal filtration.22 For example,
Unezaki et al. showed the extravasation of PEG-liposomes with
a size of ∼130 nm in tumour tissues but not in healthy
tissue.23
Here we report the use of an innovative multi-needle elec-
trohydrodynamic (EHD) device that is able to prepare multi-
layered nanoparticles that potentially fulfil the requirements of
true compartmentalization with appropriate environments,
sequential release and suitable size. In brief, the device allows
controlled co-flow of up to four diﬀerent solutions through a
capillary nozzle under the influence of an electric field.24 The
electric charge generated competes with the surface tension of
the droplet, causing it to break up into smaller droplets (micro
or nano) that undergo solvent evaporation during collec-
tion.25,26 The device operates at ambient temperature, does
not require the use of surfactants (as often required for other
nanoparticle preparation techniques) and can generate layered
particles with a controlled size distribution at a rate of 109–
1017 per minute per nozzle.27,28 The technique has shown
potential in preparing nanoparticles with three and four
layers24 hence it is entirely appropriate to explore the use of
the method in preparing the sophisticated multi-layered nano-
particles required for siRNA-based combination therapy.
A point of concern when using EHD to prepare nanoparticles
containing biologically active compounds is their degradation
under the applied electric field. However, the available litera-
ture indicates that a significant amount of work has been per-
formed on electrospun nanofibers containing nucleic acids,
including siRNA.29–31 These authors have shown that, despite
the harsh processing conditions during electrospinning, the
bioactivity of siRNA was retained and able to provide a silen-
cing eﬃciency of 61–81%.32 Considering that the technical
aspects of electrospinning are very similar to electrospraying it
is reasonable to suggest that siRNA will remain active in the
prepared nanoparticles, although further work will be required
to establish this prior to in vivo studies.
In this work, we aim to prepare three-layered nanoparticles
with an ideal size for drug delivery containing PLGA in the
inner (drug-loaded) and outer layers and siRNA-loaded chitosan
in the middle layer, as indicated schematically in Fig. 1. All the
polymeric carriers are non-toxic, biodegradable and biocompati-
ble. The inner layer of PLGA was loaded with the anti-cancer
drug cisplatin as to achieve a controlled release formulation
from the hydrophobic matrix of the polymer. Chitosan is a
cationic polymer which forms polyelectrolyte complexes with
negatively charged biomolecules such as siRNA, hence allowing
protection of the nucleic acid.33,34 The outer layer of PLGA pro-
tects the two inner compartments and allows the particle to be
taken up intact. To prevent opsonisation and particle agglo-
Fig. 1 Schematic representation of a compartmentalized three-layered
particle for combination cancer therapy containing an anti-cancer drug
(cisplatin, in this study) in the inner layer, a silencing agent (siRNA) in the
middle layer and a coating protective layer.
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meration, PEGylation or equivalent would be desirable but
this may be achieved reasonably easily once the technology is
established and hence is not considered further here. Our
intention is to develop a novel platform for the manufacture
and characterization of complex combination nanocarrier
systems using the multi-needle electrohydrodynamic system; a
successful outcome to this study will result in a generalizable
delivery approach that may be applied to a wide range of combi-
nation therapeutic approaches.
Experimental
Materials
Chitosan medium molecular weight (Molecular weight, Mw =
190 000–310 000 g mol−1) and chitosan low molecular weight
(Mw = 50 000–190 000 g mol
−1), both with a degree of deacetyla-
tion (DD) of 75–85%, were purchased from Sigma Aldrich
(Dorset, UK). Poly-(D,L-lactic-co-glycolic acid), PLGA, 50 : 50
Resomer® RG 503 H (Mw = 24 000–38 000 g mol
−1) was pur-
chased from Evonik (Darmstadt, Germany). Small interfering
RNA (siRNA) universal negative control fluorescently labelled
with Cyanine 5 (Cy5) was purchased from Sigma Aldrich (UK).
Cisplatin was obtained from Enzo (Exeter, UK). 2′7′ difluorofluor-
escein (Oregon Green®) and ProLong Diamond® antifade
mountant were obtained from Molecular Probes, Life
Technologies (Oregon, USA). Amicon Ultra-4 centrifugal filter
units with ultracel-3 membrane Mw cut-oﬀ of 50 kDa were
obtained from Merck Millipore (Cork, Ireland). HyPure molecular
biology grade was purchased from GE Healthcare Life Sciences
(Utah, USA). Tween® 80, dimethyl carbonate (DMC), acetic acid,
N,N-dimethylacetamide (DMAC) and ethanol absolute analytical
grade were obtained from Sigma Aldrich (Dorset, UK).
Solution preparation and characterization
PLGA and chitosan solutions of diﬀerent compositions were
prepared and electrosprayed so as to select those giving a
better jet stability that allowed the preparation of three-layered
nanoparticles. PLGA solutions were prepared in DMC at 3 and
6% (w/v); chitosan solutions were prepared at a concentration
of 0.05% (w/v) in 0.05% (v/v) aqueous acetic acid solution. Two
diﬀerent additives, Tween® 80 (at a concentration of 2% v/v)
and ethanol (at two diﬀerent concentrations of 20 and 30%
v/v) were added to the chitosan solution to reduce surface
tension and electrical conductivity, respectively. The solutions
showing the most promising properties were electrosprayed
and the existence of a three-layered structure was evaluated.
The same solutions were then used to prepare loaded siRNA
particles. SiRNA fluorescently labelled with Cy5 was used to
prepare siRNA-chitosan solutions at a ratio of 1 : 10. Solutions
were prepared by adding 10 µL of a 100 µM siRNA to 490 µL of
HyPure molecular biology grade water. This solution was then
added to 500 µL of chitosan 0.05% w/v and gently mixed just
before spraying. For fluorescence microscopy imaging, 1–2 mg
of Oregon Green® was added to the PGLA solution and left
stirring overnight. PLGA-cisplatin solutions were prepared at
0.1% w/v drug loading in 40 : 60 DMAC/DMC. All solutions
were prepared at the ambient temperature. The viscosity, con-
ductivity and surface tension properties of each solution were
measured prior spraying after calibrating the equipment (see
below) used.
Viscosity. Rheological measurements were performed using
an AR-1000N controlled stress rheometer (TA Instruments,
Delaware, USA). For all measurements, a parallel plate with
4 cm diameter was used.
Conductivity. Electrical conductivity of each solution was
measured using a HI-8733 (Hanna Instruments, Texas, USA).
Surface tension. Surface tension measurements were carried
out using a K9 Tensiometer – Wilhelmy plate method (KRÜSS,
Hamburg, Germany).
Four-needle coaxial electrohydrodynamic (EHD)
A four-needle coaxial EHD device was used to prepare three-
layered nanoparticles (schematic diagram of the device shown
in Fig. 2). PLGA solution was used in the outer and inner
needles while chitosan, and subsequently chitosan-siRNA solu-
tion, was introduced through the middle needle. Four needles
with inner diameters of 0.3, 0.69, 1.37 and 2.4 μm were used.
Flow rates and voltage were optimised for each solution and
were as follow (from the inner to the outer needles): 20, 20,
50 µL min−1 for the polymeric particles; 15, 15, 35 µL min−1
for the particles loaded with siRNA; 15, 10, 35 µL min−1 for the
cisplatin loaded particles and 15, 10, 50 µL min−1 for the
siRNA/cisplatin loaded systems. DMC was used in the outer-
most needle at a rate varying from 100 and 50 µL min−1. The
voltage applied was 20.4 ± 1.1 kV for the polymeric and siRNA-
loaded particles, but significantly higher for the cisplatin and
siRNA/cisplatin loaded systems which was around 28.5 ± 0.7 kV.
Fig. 2 Schematic representation of the experimental four-needle
coaxial electrohydrodynamic set-up used in this work.
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Particles were collected in a petri dish filled with absolute
ethanol at a distance of 150 mm for the polymeric and siRNA-
loaded particles and 260 mm for cisplatin and siRNA/cisplatin
loaded systems. A copper ring was placed in the extremity of
the coaxial four-needle arrangement to help focus the jet.
Dynamic light scattering (DLS)
Intensity mean hydrodynamic size and zeta potential of the
nanoparticles were measured on a Malvern Zetasizer-NanoZS
(Malvern Instruments, Malvern, UK) with a He–Ne laser (wave-
length of 632.8 nm). The measurements were carried out at a
scattering angle of 173 at 25 °C and ethanol was used as the
dispersion medium.
Encapsulation eﬃciency
The loading eﬃciency of siRNA and cisplatin was determined
by measuring the free siRNA and cisplatin concentration in
the recovered medium after particle centrifugation using a
Sigma 3-16KL centrifuge (Sigma, Osterode am Harz, Germany)
at 3000 rpm/10 min. Amicon Ultra-4 centrifugal filter units
with ultracel-3 membrane Mw cut-oﬀ of 50 kDa were used. The
siRNA concentration on the solution collected after centrifu-
gation (non-encapsulated siRNA) was measured using
NanoDrop® Lite Spectrophotometer (Thermo Scientific,
Wilmington, USA). The solution recovered after centrifugation
of polymeric nanoparticles (without siRNA and cisplatin) was
used as blank. The cisplatin concentration was measured
using UV spectroscopy at 300 nm. The siRNA encapsulation
eﬃciency (%) was given by the diﬀerence between the total
amount of siRNA added for the nanoparticles preparation and
the siRNA collected in solution after centrifugation, to the
total of siRNA added.15 The same formula was applied to
determine the encapsulation eﬃciency of cisplatin.
Scanning electron microscopy (SEM)
SEM images of the nanoparticles surface were acquired using
a FEI Quanta 200F (FEI, Eindhoven, Netherlands). To improve
electrical conductivity prior to examination, samples were
coated with gold using a Quorum Q150 T sputter gold coater
(Quorum Technologies, Lewes, UK).
Transmission electron microscopy (TEM)
TEM images were collected using a Philips CM 120 Bio-Twin
(FEI, Oregon, USA). A drop of the nanoparticles suspension (as
collected during the EHD preparation process) was placed on a
copper grid and imaged without any staining.
Super-resolution imaging using structured illumination
microscopy (SIM)
SiRNA loaded samples for SIM imaging and analysis were cen-
trifuged using a Sigma 3-16KL centrifuge (Sigma, Osterode am
Harz, Germany) at 3000 rpm for 10 min, washed with 1 mL of
absolute ethanol and centrifuged again at 3000 rpm for 5 min.
All steps were carried out at 5 °C. Ultra-4 centrifugal filter
units with ultracel-3 membrane Mw cut-oﬀ of 50 kDa were
used. A drop of the siRNA loaded samples collected in ethanol
(100%) was put on a clean glass coverslip (#1.5, 0.17 mm thick-
ness, Marienfield, Lauda-Königshofen, Germany), evenly
spread out using the pipette tip and the excess ethanol was
allowed to evaporate so that the nanoparticles stick to the
glass. The coverslips were then mounted on a microscopy
glass slide using ProLong Diamond®, as mounting medium.
The mounted samples were allowed to cure at ambient temp-
erature for a minimum of 24 h and sealed using liquid plaster
(Germolene®, Bayer, UK) before SIM imaging.
SIM images were acquired using a commercial Zeiss ELYRA
PS.1 microscope equipped with a pco.edge sCMOS camera
(2048 × 2048 pixels). A Zeiss 63× Plan-Apochromat DIC M27 oil
objective lens (1.4 NA, 0.19 mm working distance) was used
for all image acquisitions. Fluorescence was excited using a
488 nm (BP 495-550 + LP750 emission filter) and 642 nm (LP
655 emission filter) laser at 1.8 mW power, sequentially, and
an exposure time of 200 ms was used. SIM gratings with a
period of 28 µm and 34 µm were used with the 488 nm and
642 nm laser respectively. Sixteen-bit images (62.58 µm ×
62.58 µm, 1942 × 1942 pixels) were acquired using 3 rotations
and 5 phase shifts of the gratings in each slice of the Z-stack
(2.63 µm total range, 110 nm steps).
All SIM images were processed using the Structured
Illumination algorithm within the Zeiss acquisition software
(ZEN Black). The 488 nm channel was processed selecting 3D
and using the Automatic setting. The 642 nm channel was ana-
lysed in the 3D mode as well, but using the Manual settings
and selecting Maximum Isotropy to remove some high fre-
quency noise. Resolutions between ∼99–130 nm were
obtained.
Following the Structured Illumination processing all
images were corrected for daily chromatic shifts between the
488 and 642 nm channel by applying a channel alignment
table obtained from processing a 4 µm z-stack of 200 nm
TetraSpeck beads (Molecular Probes) using the Channel
Alignment tool (aﬃne alignment) in ZEN black.
Energy dispersive spectroscopy – scanning electron
microscopy (EDS–SEM)
Samples were mounted directly on SEM holders, carbon
coated and examined with a S-3400N microprobe (Hitachi,
Illinois, USA). An Oxford Instruments X-sight Energy
Dispersive Spectrometer (EDS) and INCA analytical software
package were used to collect and process compositional data.
The excitation voltage was set as 10 kV and the beam current
at 50 nA for a working distance of 10 mm.
Results and discussion
The preparation of multi-layered nanoparticles with a con-
trolled size distribution and morphology using EHD primarily
relies on having a stable cone-jet mode during the process. To
achieve a stable cone-jet, the complex inter-dependence
between the solution properties (concentration, viscosity,
surface tension and electrical conductivity) and processing
Paper Nanoscale
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parameters (flow rate, voltage and collection distance) should
be carefully considered and interconnected. Below we present
both the solution optimization steps and processing para-
meters we adjusted to improve the stability of the jet during
the spraying process of the diﬀerent solutions.
Solutions optimization and characterization for the
preparation of the polymeric nanoparticles
As previously mentioned earlier, we aim to prepare three-
layered nanoparticles containing PLGA-chitosan-PLGA. PLGA
is a hydrophobic polymer and solutions were prepared in
dimethyl carbonate (DMC) at concentrations of 3 and 6% w/v.
On the other hand, chitosan is only soluble in slightly acidic
aqueous conditions and therefore solutions were prepared in
0.05% v/v aqueous acetic acid. When using EHD it is impor-
tant that the solutions properties are similar in terms of their
surface tension and conductivity but should ideally be immis-
cible since this can facilitate the formation of individualized
layers. In this case, PLGA and chitosan solutions have comple-
tely distinct properties which can lead to diﬃculties during
spraying. Table 1 presents the characterization of the diﬀerent
chitosan solutions prepared with medium and low molecular
weight and with diﬀerent additives (ethanol and Tween® 80),
aimed to achieve a desirable stable cone-jet mode. The pro-
perties of the PLGA solutions are also shown.
We started by adding 20% ethanol to the medium Mw chito-
san solution (0.05% w/v chitosan in 0.05% v/v acetic acid) to
reduce both surface tension and conductivity (solution A).
Attempts to electrospray this solution were not successful
since a stable jet could not be achieved and fiber formation
was observed due to the high viscosity of the solution. In the
next step, Tween® 80 at 2% v/v was added (solution B). The
addition of Tween® 80 reduced surface tension (compared to
solution A) but it substantially increased the electrical conduc-
tivity of the solution. Higher conductivity can lead to disentan-
glement of the polymer network during electrospraying result-
ing in a very unstable jet.35 In order to find a good balance
between these three properties, we reduced the viscosity of
solution A by using low molecular weight chitosan at the same
concentration (0.05% w/v) and used 30% v/v ethanol instead of
Tween® 80 2% v/v which allowed the reduction of both surface
tension (compared to solution A) and electrical conductivity
(compared to solution B). Solution C was therefore selected for
further experiments. PLGA solutions at a concentration of 6
and 3% w/v for the inner and outer layers were also tested,
although the higher concentration (solution D) led to the for-
mation of fibres, thus solution E (3% PLGA) was then used for
the two layers in the particle preparation.
Processing parameters
Once the solution properties were optimised, other parameters
such as flow rate, voltage applied, collection medium and dis-
tance of collection, also needed to be considered. The values
for each parameter have been described in the methodology
section. We noted that although the properties of the solutions
have been carefully optimized, the stability of the jet still
needed further improvement due to the large electrical con-
ductivity diﬀerences between the two solutions. Therefore, as
an attempt to isolate the solution with higher conductivity
(chitosan solution), often referred to as the driving liquid/solu-
tion, we used pure DMC in the fourth needle of the coaxial
EHD, which significantly enhanced the jet stability during pro-
cessing. DMC is a green solvent with low hazard properties for
human health and environment in comparison to other
solvent alternatives that mainly evaporates during electrospray-
ing without causing any disruption to the particle formation.36
As a result, the amount of DMC in the final particles is
expected to be residual and have minimal impact to the
human health. We also found that the use of a copper ring
placed in the tip of the coaxial needle aided the stabilization
of the electrospraying process (video 1 in ESI†). Another para-
meter to account for is the collection medium. When hydro-
phobic polymers are used, agglomeration can be an issue, as
we observed when collecting the samples in distilled water
where a thin film of particles formed on the surface of the
medium. To overcome this issue, we used ethanol as the col-
lection medium which allowed a well dispersed suspension to
be collected.
In comparison to other available chemical or physical
methods used to prepare nanoparticulate systems, numerous
advantages make EHD an attractive technique for drug delivery
purposes. These include: (i) processing at room temperature;
Table 1 Measurements of the physical properties (viscosity, surface tension and electrical conductivity) of the diﬀerent solutions used to prepare
three-layered polymeric nanoparticles. Chitosan of low (50 000–190 000 g mol−1) and medium (190 000–310 000 g mol−1) molecular weight and
PLGA (24 000–38 000 g mol−1) at diﬀerent concentrations were tested
Solution Chitosan Mw Concentration [%] Additives (v/v)
Properties
Viscosity
[mPa . s]
Surface tension
[mN m−1]
Conductivity
[µS m−1]
Chitosan A Medium 0.05 Ethanol (20%) 12.5 ± 0.5 37.1± 0.3 73
B Medium 0.05 Ethanol (20%) + Tween 80 (2%) 8.5 ± 0.4 31.7 ± 0.5 191
C Low 0.05 Ethanol (30%) 9.5 ± 0.3 36.5± 0.6 48.2
PLGA D N/A 6 N/A 3.0 ± 0.1 30.4 ± 0.5 0
E N/A 3 N/A 1.4 ± 0.3 29.4 ± 0.3 0
N/A – not applicable.
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(ii) particles are dried during the process (no requirement for
an additional drying step); (iii) control of the particle size and
morphology by adjusting process parameters and solution
characteristics. Furthermore, this manufacturing technique is
low cost and durable, with a particle production rate of more
than 109–1017 per minute per nozzle achievable which is a
well-known limitation of other conventional methods, i.e.,
emulsion-solvent evaporation and lipid based techniques.
Characterization of the unloaded, mono- and dual-loaded
nanoparticles
After optimizing the properties of the solutions and adjusting
the processing parameters, nanoparticles containing chitosan
solution C in the middle layer and PLGA solution E in the
inner and outer layers were prepared and characterized in
terms of their size, morphology and internal structure. The
subsequent step involved loading of the middle chitosan layer
with a negative control fluorescently labelled siRNA-Cy5, and
the inner PLGA layer with cisplatin to show proof of concept
that each active ingredient can be incorporated in the desired
layer for further combination therapy applications.
Size distribution and encapsulation eﬃciency. The Z-average
size distribution, polydispersity index (Pdl) and zeta potential
values of unloaded and loaded samples were measured using
dynamic light scattering (DLS). All samples, except for the cis-
platin-loaded nanoparticles (NPs), were found to have a high
homogeneity and narrow size distribution, as shown in Fig. 3.
The Z-average and zeta potential values were found to be as
follows: 122.2 ± 0.6 nm (Pdl = 0.07 ± 0.02) and +23.7 mV for
the polymeric NPs; 265.2 ± 3.5 nm (Pdl = 0.14 ± 0.01) and
−15.5 mV for the siRNA-loaded NPs; 512.3 ± 3.4 nm (Pdl =
0.22 ± 0.01) and +36.6 mV for the cisplatin-loaded NPs; and
finally 235.2 ± 3.72 nm (Pdl = 0.12 ± 0.02) and −38.3 mV for
the system containing both siRNA and cisplatin. The results
showed an increase in particle size for the loaded samples
which was particularly evident for the NPs loaded with cispla-
tin only. In addition, the particle size distribution for this
sample was found to be much broader in comparison to the
other samples. This could be explained by the rise in electrical
conductivity for the cisplatin-PLGA solution (1.16 µS) in com-
parison to the pure PLGA solution (0 µS) which was reflected
by a less stable jet during spraying. The fact that the dual
system containing siRNA and cisplatin was not aﬀected might
be due to the presence of siRNA which, by interacting with the
positively charged chitosan, leads to an overall decrease in
electrical conductivity of the system. Regarding the zeta poten-
tial measurements, all systems that did not contain siRNA
have a positive surface charge (presence of positively charged
chitosan). In contrast, siRNA and dual-loaded NPs showed a
negative surface charge caused by the presence of phosphate
groups in the siRNA structure.
The encapsulation eﬃciency (EE) of siRNA and cisplatin
into the particles was found to be 71.9 ± 5.5% and 83.8 ±
3.5%, respectively. Studies have reported a loading eﬃciency
of siRNA in chitosan-PLGA nanoparticles to vary between 4.3%
and 77.7% depending on the amount of chitosan added to
prepare the particles, with the highest EE observed with a
higher percentage of chitosan present.37 One of the main
advantages when using EHD to prepare nano and microparti-
cles is its high encapsulation eﬃciency when compared to
other preparation techniques;38 this appears to be the case in
the current study as well.
Morphology and internal structure. We have shown that
EHD, with the appropriate set of parameters, can be success-
fully used to prepare particles with a suitable diameter and
narrow size distribution. The next step involved the character-
ization of the external morphology and internal structure of
the particles. For this we have used a range of imaging tech-
niques, as shown in the sections below.
Electron microscopy. Scanning electron microscopy (SEM)
and transmission electron microscopy (TEM) were used to
characterize the external morphology and internal structure of
the particles, respectively. Fig. 4 presents SEM micrographs
taken for each individual system. Polymeric (a, b), siRNA-
loaded (c, d) and siRNA/cisplatin loaded system NPs (g, h)
were shown to have a spherical and relatively uniform shape.
This is an important factor for cellular uptake and biodistribu-
tion in vivo. Studies have shown that nanoparticles with a
spherical architecture are taken up more rapidly by cells com-
pared to rod-shaped nanoparticles.39 In contrast, and as
expected based on the DLS results, cisplatin-loaded NPs
showed a less uniform shape, with some appearing to be fused
together.
Fig. 5 below shows the TEM images for the polymeric (a, b),
mono-loaded siRNA (c, d) and cisplatin (e, f ) systems and
siRNA/cisplatin loaded particles (g, h). TEM is an essential
characterization tool for directly imaging nanomaterials to
obtain quantitative measures of particle size, size distribution,
and morphology. Amplitude and phase variations in the trans-
mitted beam provide imaging contrast that is a function of the
sample thickness (the amount of material that the electron
beam must pass through) and the sample material (heavier
Fig. 3 Size distribution proﬁles obtained by dynamic light scattering
measurements for the polymeric, individually loaded (siRNA and cispla-
tin) and siRNA/cisplatin loaded nanoparticles.
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Fig. 4 Scanning electron microscopy images of polymeric (a, b), siRNA (c, d), cisplatin (e, f ) and siRNA/cisplatin loaded particles (g, h). Micrographs
were recorded at two diﬀerent magniﬁcations and scale bars are displayed in each image.
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atoms scatter more electrons and therefore have a smaller elec-
tron mean free path than lighter atoms). Therefore, successful
imaging of nanoparticles using TEM depends on the contrast
of the sample relative to the background. In this study, all the
materials were carbon-based with little contrast between them.
However, it is still possible to identify a three-layered internal
structure in all samples. PLGA is a more electron dense
polymer and therefore has a dark appearance in TEM while
chitosan appears as a lighter layer in the middle of the two
PLGA layers. However, to confirm the existence of individua-
lized layers a florescent-based microscopic technique was
necessary as shown below.
Fig. 5 Transmission electron microscopy images of polymeric (a, b), mono-loaded siRNA (c, d) and cisplatin (e, f ) systems and siRNA/cisplatin
loaded particles (g, h). Micrographs were collected without any staining at two diﬀerent magniﬁcations. Scale bars are shown in each image.
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Amongst all the prepared systems, cisplatin-loaded NPs (e,
f ) again showed a much less uniform spherical shape com-
pared to the rest of the samples. SiRNA-loaded NPs (single and
dual systems) showed a homogeneous spherical shape. Due to
its polycationic nature, chitosan may form polyelectrolyte com-
plexes with negatively charged molecules, such as may be the
case with siRNA.15
Super-resolution imaging using structured illumination
microscopy (SIM). SIM was used to resolve the internal struc-
ture of the nanoparticles. Due to the diﬀraction of light the
resolution of optical systems has been limited according to the
Abbe limit of resolution (d = λ/2 × NA, where d is the resolu-
tion, λ the excitation wavelength and NA the numerical aper-
ture of the objective lens used for the imaging). Using a 63−
objective lens with an NA of 1.4 as shown here the limit of
lateral resolution would therefore be ∼200 nm depending on
the excitation wavelength. SIM is capable of approximately
doubling the lateral resolution by superimposing a grid
pattern on the sample whilst acquiring wide-field fluorescence
images and subsequent processing of the raw data with a
specialized algorithm that allows to extract high-frequency
information to produce the final super-resolution SIM
image.40 The sample purification including the centrifugation
time and speed before depositing the nanoparticles onto glass
coverslips was found to be crucial for the quality of images
that were obtained. Fig. 6 shows a sequence of images collected
at diﬀerent planes (Z-stack). Oregon Green® was added to the
PLGA solution (shown in green) and siRNA was labelled with
Cy5 (shown in orange) for fluorescence SIM. Samples were col-
lected in ethanol, centrifuged to remove non-encapsulated
material, deposited on high precision glass coverslips and
mounted on a glass slide using ProLong Diamond®.
Encapsulated nanoparticles showed a green layer surrounding
an inner red layer. Due to the resolution limitation of the tech-
nique, the inner PLGA layer cannot be observed. The size of the
particles appeared to be slightly larger when compared with the
measurements obtained with DLS and TEM, however we need
to take into account the blooming eﬀect of the fluorophores
which can have a significant influence at this size range.
With SIM it is possible to record images at diﬀerent focal
planes enabling the entire volume of the sample to be visualized.
Z-stacks are generated by incrementally stepping through the
sample using a piezoelectric motor. Furthermore, Z-stacks repre-
sent a very straightforward means to analyze the entirety of thin
fluorescent samples. This allows 3D reconstruction of images
which provides helpful visual information at a higher resolution
level.41 A 3D video of a single particle is supplied in ESI (video 2†).
SIM imaging allowed us to resolve the outer and the middle
layer of the nanoparticles. The resolution of this technique is not
suﬃcient though to resolve the core of the nanoparticles as it is
limited to approximately twice the diﬀraction resolution limit of
a fluorescence microscope. Other super-resolution techniques
Fig. 6 Super resolution-structured illumination microscopy images
(Z-stack) of the particles labelled with PLGA-Oregon Green® (green)
and siRNA-Cy5 (orange). The Z-step size was 110 nm. Scale bar for all
images is 0.2 µm long.
Fig. 7 Detection of cisplatin in the three layered nanoparticles by EDS-SEM. (a) SEM image showing the characterized particle (location highlighted
by red outline); (b) EDS elemental spectrum composition showing the presence of platinum when the selected particle was analyzed. Three-layered
polymeric particles (non-loaded) were used as a negative control (c) and (d).
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such as Stimulated Emission Depletion (STED)42 microscopy or
Stochastic Optical Reconstruction Microscopy (STORM)43 are
known to provide a higher resolution than SIM and might there-
fore be useful tools to study the composition of these multilayer
nanoparticles, and particularly their core, in future studies.
Energy dispersive spectroscopy – scanning electron
microscopy (EDS–SEM). EDS enables localization by compo-
sitional detection because the intensity of a particular elemen-
tal signal in an EDS spectrum can be mapped to an EM image.
Fig. 7 above shows the SEM image (a) of a three-layered nano-
particle containing cisplatin and the spectrum of elemental
composition detected by using EDS (b). Non-loaded three
layered polymeric particles were used as a negative control
(c–d). By looking at the spectrum it is possible to confirm the
presence of cisplatin in the particle. Unfortunately, due to the
limitations of the technique the exact location of cisplatin
within particle could not be directly ascertained. However, on
consideration of the EHD process (co-axial needle arrange-
ments) and the fact that the solutions are immiscible due to
diﬀerences in polarity, it is perfectly reasonable to assume that
cisplatin is present in the inner layer. Attempts to use
EDS-TEM were unsuccessful due to the high voltage of TEM
(200 kV) that led to the destruction of the sample.
Conclusions
The study has outlined the manufacture and characterization
of trilayered nanoparticles containing distinct environments
for the combined administration of low molecular weight che-
motherapeutic agents and resistance-reducing nucleic acids,
using cisplatin and fluorescently labelled siRNA as models for
the two therapeutic agents. The parameters associated with
successful particle manufacture (viscosity, electrical conduc-
tivity and surface tension) have been explored, while size and
surface charge measurements have allowed the eﬀect on agent
incorporation on particle characteristics to be ascertained.
A range of imaging techniques has been employed that have
allowed the confirmation of the presence of the agents in their
respective layers as well as allowing the architecture of the tri-
layered systems to be studied. It was found that the particles
were of a size commensurate with EPR uptake and the loading
eﬃciency was high. Overall, the study has shown that it is
possible to produce truly compartmentalized nanoparticles
which are capable of encapsulating agents with very diﬀerent
structures and environmental requirements in a manner that
lends itself to larger scale production. This in turn suggests
that multi-needle EHD represents a potentially highly useful
and practical platform for combination therapy approaches.
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